Kalaris Therapeutics (KLRS) awards director 18,000 stock options
Rhea-AI Filing Summary
Kalaris Therapeutics, Inc. reported that director Laurie Keating received a grant of stock options covering 18,000 shares of common stock, with a $3.51 exercise price and expiring on July 31, 2036. The options vest in equal monthly installments over three years from August 1, 2026 through August 1, 2029, subject to continuous service, resulting in 18,000 options directly held after this award.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
KEATING LAURIE
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 18,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 18,000 shares (Direct)
Footnotes (1)
- F1. The option was granted on August 1, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from August 1, 2026 through August 1, 2029, subject to continuous service.
Key Figures
Stock options granted: 18000.0000 options
Exercise price: $3.5100 per share
Expiration date: 2036-07-31
+3 more
6 metrics
Stock options granted
18000.0000 options
Grant to director Laurie Keating on August 1, 2026
Exercise price
$3.5100 per share
Exercise price of the stock option award
Expiration date
2036-07-31
Option expiration date for the granted stock options
Underlying shares
18000.0000 shares
Common shares underlying the granted stock options
Vesting start date
August 1, 2026
Vesting begins on this date in equal monthly installments
Vesting end date
August 1, 2029
Final vesting date, subject to continuous service
Key Terms
Stock Option (Right to Buy), exercise price, vesting, continuous service
4 terms
Stock Option (Right to Buy) financial
"Security titled "Stock Option (Right to Buy)" was granted."
exercise price financial
"The option has a conversion or exercise price of $3.5100 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares underlying the option are scheduled to vest over three years."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
continuous service other
"Vesting runs through August 1, 2029, subject to continuous service."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did KLRS report for director Laurie Keating?
Kalaris Therapeutics (KLRS) reported that director Laurie Keating received a grant of stock options covering 18,000 shares of common stock. This is a compensation-related award, not an open-market purchase or sale of existing shares.
How many Kalaris Therapeutics (KLRS) stock options did Laurie Keating receive?
Laurie Keating was granted 18,000 stock options linked to an equal number of common shares of Kalaris Therapeutics. These options were reported as directly owned following the transaction and represent a new equity-based compensation award.
What is the exercise price and expiration date of Laurie Keating’s KLRS options?
The stock options granted to Laurie Keating have a $3.51 exercise price per share and expire on July 31, 2036. This sets the price at which she can purchase KLRS common stock before the expiration date, subject to vesting and service conditions.
How do Laurie Keating’s KLRS stock options vest over time?
The 18,000 KLRS stock options granted to Laurie Keating are scheduled to vest over three years in equal monthly installments. Vesting runs from August 1, 2026 through August 1, 2029 and is conditioned on her continuous service with the company.
Was Laurie Keating’s KLRS option grant made under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox was not marked as affirmative, and there is no footnote indicating a trading plan. This grant appears as standard equity compensation rather than a transaction executed under a pre-arranged 10b5-1 plan.
What ownership type is reported for Laurie Keating’s new KLRS stock options?
The 18,000 stock options granted to Laurie Keating are reported as directly owned. There is no indication they are held through a trust, fund, or other indirect entity, and no footnote disclaims her beneficial ownership of this award.